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A subgroup of breast cancers has several metabolic compart-
ments. Themechanismsbywhichmetabolic compartmentaliza-
tion develop in tumors are poorly characterized. TP53 inducible
glycolysis and apoptosis regulator (TIGAR) is a bisphosphatase
that reduces glycolysis and is highly expressed in carcinoma
cells in the majority of human breast cancers. Hence we set out
to determine the effects of TIGAR expression on breast carci-
noma and fibroblast glycolytic phenotype and tumor growth.
The overexpression of this bisphosphatase in carcinoma cells
induces expression of enzymes and transporters involved in the
catabolism of lactate and glutamine. Carcinoma cells overex-
pressing TIGAR have higher oxygen consumption rates and
ATP levels when exposed to glutamine, lactate, or the combina-
tion of glutamine and lactate. Coculture of TIGAR overexpress-
ing carcinoma cells and fibroblasts compared with control
cocultures induce more pronounced glycolytic differences
between carcinoma and fibroblast cells. Carcinoma cells over-
expressing TIGAR have reduced glucose uptake and lactate
production. Conversely, fibroblasts in coculture with TIGAR
overexpressing carcinoma cells induce HIF (hypoxia-inducible
factor) activation with increased glucose uptake, increased
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3),
and lactate dehydrogenase-A expression. We also studied the
effect of this enzyme on tumor growth. TIGAR overexpression
in carcinomacells increases tumor growth in vivowith increased
proliferation rates. However, a catalytically inactive variant of
TIGAR did not induce tumor growth. Therefore, TIGAR
expression in breast carcinoma cells promotes metabolic com-
partmentalization and tumor growth with a mitochondrial
metabolic phenotype with lactate and glutamine catabolism.
Targeting TIGAR warrants consideration as a potential ther-
apy for breast cancer.
Multiple metabolic compartments exist in human tumors
including breast cancer (1). There is metabolic coupling with
lactate transfer between highly glycolytic carcinoma cells and
carcinoma cells with reduced glycolysis inmodels of vulvar and
colon cancer (2). High stromal glycolysis with low cancer cell
glycolysis have also been described in breast, ovarian, prostate,
bladder, head and neck carcinomas, and sarcomas (3).
The interactions between carcinoma cells and fibroblasts in
breast cancer play an important role in tumor progression.
Fibroblasts have been shown to promote breast cancer tumor
growth (4) and metastasis (5). Carcinoma cell invasiveness and
resistance to chemotherapy in breast cancer are induced by
fibroblasts (6). It is unknown how cancer cell metabolism in
breast cancer modulates adjacent fibroblast metabolism.
TP53-induced glycolysis and apoptosis regulator (TIGAR)2
is an inhibitor of glycolysis and is highly expressed in themajor-
ity of human breast-invasive ductal carcinomas (7, 8). TIGAR is
the only known phosphatase glycolytic modulator regulated by
TP53. It is unknown if TIGAR induces aggressive breast cancer.
The human TIGAR gene is similar to the bisphosphatase
domain of the glycolytic enzyme 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase (PFKFB) (7). TIGAR decreases
glycolysis by functioning as a bisphosphatase that reduces levels
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of intracellular fructose-2,6-bisphosphate (Fru-2,6-P2) and 2,3-
bisphosphoglycerate (7, 9), which are regulators of glycolysis.
Phosphofructokinase-1 (PFK-1) is a key glycolytic enzyme
that converts fructose 6-phosphate to fructose 1,6-bisphos-
phate. PFK-1 is allosterically activated by Fru-2,6-P2 (10). Also,
Fru-2,6-P2 is an inhibitor of fructose-1,6-bisphosphatase,
which opposes the activity of PFK-1 by converting fructose 1,6-
bisphosphate to fructose 6-phosphate (10).
The synthesis and breakdown of Fru-2,6-P2 depends on the
bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphos-
phatase isoenzymes, products of four genes (PFKFB1–4) that
code for the different PFKFB isoenzymes and that have distinct
cell expression patterns and display different kinase/bisphos-
phatase activity ratios and control by different protein kinases
(10–12). In tumor cells, the concentration of Fru-2,6-P2 is gen-
erally elevated due to overexpression and activation of PFKFB3,
which has opposite effects of TIGAR (11–13). Conversely,
TIGAR depletion increases glycolytic flux by increasing the
activity of PFK-1 and the glycolytic flux by increasing Fru-
2,6-P2 levels (7, 14). It is unknown if TIGAR modulates catab-
olism of other substrates such as lactate and glutamine, which
have been shown to be alternate catabolites to glucose for car-
cinoma cells (1). TIGAR expression has been shown to be
inversely associated with glycolysis as TIGAR expression was
inversely associated with 2-deoxyglucose uptake on PET scans
in subjects with non-small cell lung cancer (15). TIGAR regu-
lates hexokinase 2 (HK2) activity and increases mitochondrial
membrane potential, but the effect of TIGAR onmitochondrial
metabolism, oxygen consumption rates, and ATP generation is
unknown (16). In sum, TIGAR reduces glycolysis, but its effects
on the catabolism of other substrates and mitochondrial
metabolism is poorly characterized.
TIGAR has been reported to mediate human cancer aggres-
siveness, although the mechanism is unclear, and its effect in
breast cancer is unknown. In addition to reducing glycolysis,
TIGAR reduces apoptosis (7). TIGAR is overexpressed in naso-
pharyngeal carcinoma, and genetic overexpression increases
tumor growth with carcinoma cell growth, colony formation,
migration, and invasion with NFB activation in carcinoma
cells (17). Knockdown of this bisphosphatase induces apoptosis
of HepG2 hepatocellular carcinoma cells (18). TIGAR down-
regulation in HepG2 carcinoma cells reduces the size of hepa-
tocellular carcinoma xenografts (19). TIGAR reduces apoptosis
rates of non-small cell lung cancer H-1299 and osteosarcoma
U2OS cells (7). TIGAR is also overexpressed in the majority of
glioblastomas, protecting cells from starvation-induced cell
death by up-regulating respiration and improving cellular
redox homeostasis (20). Radiosensitization of glioma cells also
occurs with TIGAR knockdown (14). However, another study
has shown that TIGAR decreases cell viability in glioblastoma
(21). TIGAR is required for proliferation of small intestine
cells (22). TIGAR null mice have decreased tumorigenesis and
increased survival in a model in which the tumor suppressor
adenomatous polyposis coli (APC) is deleted in LGR5 intesti-
nal stem cells (22). TIGAR is highly expressed in themajority of
breast cancers and carcinoma cells in breast cancer frequently
have low rates of glycolysis and apoptosis (7, 8, 24, and 25).
However, no reports have described the effect of TIGAR on
breast cancer tumor growth in vivo. Also, the role of TIGAR in
the low rates of glycolysis and apoptosis with high proliferation
observed in human breast cancer is unknown.
Breast tumors have high expression of mitochondrial bio-
genesis transcription factors and mitochondrial markers of
oxidative phosphorylation (OXPHOS) (26) (27). Multiple met-
abolic compartments exist in human malignancies (28). Meta-
bolic compartmentalization occurs in breast cancer with highly
glycolytic stromal cells and cancer cells with high OXPHOS
(28). There are no data on the metabolic effects of TIGAR
expression in breast cancer and if it plays a role in metabolic
compartmentalization or heterogeneity in tumors.We hypoth-
esize that TIGAR expression in carcinoma cells induces aggres-
sive disease with utilization of alternative catabolites to glucose
and metabolic compartmentalization.
Results
TIGAR Induced Markers of Lactate and Glutamine Catabo-
lism with Increased NADPH in Carcinoma Cells—To investi-
gate the effects of TIGAR on markers of lactate and glutamine
utilization, we overexpressed TIGAR in breast carcinoma cells.
TIGAR overexpression up-regulated moderately monocar-
boxylate transporter 2 (MCT2) protein and mRNA expression
(Fig. 1, A and B). MCT2 is a lactate importer. TIGAR also up-
regulates lactate dehydrogenase B (LDH-B), which is the
enzyme that converts lactate into pyruvate for mitochondrial
metabolism (Fig. 1C) and TIGAR up-regulates glutaminase 1
(GLS1) modestly, which is the rate-limiting enzyme in gluta-
mine catabolism and converts glutamine to glutamate (Fig. 1D).
Conversely, glutamate ammonia ligase (GLUL), which is the
enzyme that mediates glutamine synthesis from glutamate and
ammonia, was down-regulated with TIGAR overexpression
(Fig. 1E). TIGAR markedly decreased the NADP/NADPH
ratio (Fig. 1, F and G), which is consistent with increasing flux
through the pentose phosphate pathway.
TIGAR Induced OXPHOS and ATP Generation in the Pres-
ence of Lactate and Glutamine—To investigate the effects of
TIGARonmitochondrial biogenesis, we studied the expression
of peroxisome proliferator-activated receptor  coactivator 1
(PGC1) and nuclear respiratory factor 1 (NRF1). TIGAR over-
expression induced these markers of mitochondrial biogenesis
(Fig. 2A).
To investigate the effects of TIGAR and exposure to gluta-
mine and lactate onOXPHOS,we studied oxygen consumption
rates (OCR) in control and TIGAR-overexpressing carcinoma
cells. Oxygen consumption rates were higher for TIGAR over-
expressing carcinoma cells exposed to glutamine, lactate, or
glutamine and lactate compared with carcinoma cells express-
ing the control vector (p 0.05) (Fig. 2B). TIGAR overexpress-
ing carcinoma cells exposed to glutamine have a 1.2-fold
greaterOCR than control carcinoma cells exposed to glutamine
(p 0.05) and 1.5-fold greater OCRwhen exposed to lactate or
glutamine and lactate than the control carcinoma cells exposed
to the same conditions (p 0.05). OCRs were not increased by
glutamine or lactate in the absence of TIGAR overexpression.
TIGAR overexpressing carcinoma cells had lower OCR than
control cells (0.8-fold) when cultured with glucose but without
glutamine and lactate (p 0.05).
TIGAR Reprograms Breast CancerMitochondrial Metabolism
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Next, we studied the markers of OXPHOS metabolism
MITONEET, and Transporter of the Outer Mitochondrial
Membrane Member 20 (TOMM20). Both MITONEET and
TOMM20 are up-regulated by TIGAR (Fig. 2C). TOMM20
overexpression in carcinoma cells also increased expression of
TIGAR (Fig. 2D). Exposure of carcinoma cells to lactate, gluta-
mine, or glutamine and lactate increased ATP generation
(Fig. 2E).
We then exposed control and TIGAR-overexpressing carci-
noma cells to 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
(3PO), which is a PFKFB3 inhibitor that reduces Fru-2,6-P2
levels. Control cells exposed to 3PO do not have a significant
change in ATP levels (Fig. 2F). However, TIGAR-overexpress-
ing cells exposed to 3PO increased ATP levels (Fig. 2F).
Fibroblasts Induced Aggressive T47D Cells with Increased
TIGAR Expression, Reduced Expression of Glycolytic Markers,
Increased Proliferation, and Decreased Apoptosis—To investi-
gate stromal-epithelial interactions, we used a coculture model
system composed of 1) human fibroblasts immortalized with
the telomerase catalytic domain (hTERT-BJ1 fibroblasts) and
2)T47DorMCF7 cells, which arewell established breast cancer
cell lines.
TIGAR and PFKFB3 are markers of glycolysis, although they
have opposite effects. TIGARmRNA expression was increased
1.5-fold in T47D cells in coculture (p  0.01) (Fig. 3A) and
1.6-fold inMCF7 cells in coculture (p 0.05), whereas PFKFB3
mRNA expressionwas reduced 1.9-fold inMCF7 cells in cocul-
ture (p 0.05) (Fig. 3B). No statistically significant difference in
PFKFB3 mRNA expression was noted in T47D cells in cocul-
ture (Fig. 3A).
Fibroblasts induced TIGAR expression in carcinoma cells
(Fig. 3C), and TIGAR induced aggressive carcinoma cells with
increased proliferation and reduced apoptosis. Carcinoma cells
cocultured with fibroblasts had a 4.7-fold increase in DNA syn-
thesis at the expense of G0-G1 and G2-M (p  0.01) (Fig. 3D).
Carcinoma cells also had a 2-fold decreased apoptosis rate
when in coculture with fibroblasts (p 0.05) (Fig. 3E).
TIGAR Reduced Glycolysis in Carcinoma Cells and Increases
Glycolysis in Fibroblasts—We studied 2-deoxyglucose uptake
in T47D cells overexpressing TIGAR in coculture with fibro-
blasts by measuring fluorescence of 2-(N-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG), which is a
green fluorescent 2-deoxyglucose compound. 2-NBDG up-
take correlates with glycolysis with higher uptake indicating
increased glycolysis. T47D cells overexpressing TIGAR had a
1.3-fold reduced 2-NBDGuptake comparedwith control T47D
cells in coculture (p 0.05) (Fig. 4A). T47D cells overexpress-
ing TIGAR in homotypic culture had no statistically significant
FIGURE 1. Effect of TIGAR onmarkers of catabolism and NADPH in carcinoma cells. T47D cells and MDA-MB-231 cells overexpressing TIGAR and control
cells were cultured and lysed and subjected to immunoblot analysis for TIGAR and MCT2 (A), MCT2 mRNA expression as -fold change relative to control (B),
LDHB protein expression (C), GLS1 protein expression (D), and GLUL (glutamate ammonia ligase) protein expression in T47D cells (E), NADP/NADPH ratio in
T47D and MDA-MB-231 cells (F and G) .
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difference in 2-NBDG uptake compared with control T47D
cells (data not shown). T47D cells overexpressing TIGAR had a
1.9-fold reduced lactate production compared with control
T47D cells (p  0.05) (Fig. 4B). TOMM20 overexpression in
carcinoma cells also reduced lactate production 1.9-fold (p 
0.05) (Fig. 4C). Lactate production is a measure of glycolysis
with lower lactate levels indicating lower glycolysis. Hence the
effect of TIGAR on glycolysis can be phenocopied by expres-
sion of TOMM20. Monocarboxylate transporter 1 (MCT1) is
themain importer of lactate into cells and is inversely related to
rates of glycolysis. TIGAR overexpression in carcinoma cells
up-regulated MCT1 protein expression (Fig. 4D). Conversely
TIGAR down-regulation in carcinoma cells using CRISPR-
Cas9 reduced MCT1 expression (Fig. 4E–F).
TIGAR inCarcinomaCells Induced aGlycolytic Phenotype in
Fibroblasts—Next we studied the effect of TIGAR overexpres-
sion in T47D cells on fibroblast metabolism. Fibroblasts cocul-
tured with T47D cells overexpressing TIGAR had a 1.2-fold
increase in 2-NBDG uptake compared with fibroblasts in con-
trol cocultures (p  0.05) (Fig. 5A). Glucose uptake in fibro-
blasts was measured by quantifying green fluorescence of
the 2-deoxyglucose compound 2-NBDG. 2-Deoxyglucose and
2-NBDG uptake is an additional measure of glycolysis with
lower uptake indicating reduced glycolysis. PFKFB3 and
LDH-A expression increased in fibroblasts cocultured with
TIGAR overexpressing carcinoma cells (Fig. 5, B and C).
PFKFB3 and LDH-A are markers of glycolysis. LDH-B expres-
sion is reduced with coculture with TIGAR overexpressing car-
cinoma cells (Fig. 5C). LDH-B has opposite effects to LDH-A,
converting lactate to pyruvate. We next assessed the effect of
TIGARon activation of hypoxia-inducible factor (HIF) in fibro-
blasts by using a HIF1A luciferase reporter as HIF1A is one of
the main glycolytic transcription factors. NIH3T3 fibroblasts
stably transfected with a HIF1A luciferase reporter were cul-
tured with control T47D cells or TIGAR-overexpressing T47D
cells. Activation of HIF1A is increased by 1.6-fold (p 0.05) in
fibroblasts cocultured with T47D cells overexpressing TIGAR
cells in 0.5% O2 hypoxia compared with control coculture con-
ditions (Fig. 5D). Note that there was no significant change in
HIF1A activation in normoxia between control coculture and
FIGURE2.Effect of TIGARonmitochondria. T47Dcells overexpressing TIGARand control cellswere cultured and lysed and subjected to immunoblot analysis
for PGC1 and NRF1 (A). B, oxygen consumption was measured in control T47D cells (blue bar) and with TIGAR overexpression (red bar); relative concentration
is shown. Cells were cultured with control media, control with 2mM glutamine, control with 10mM lactate, or control with 2mM glutamine and 10mM lactate.
C, T47D andMCF7 cells overexpressing TIGAR and control cells were cultured and lysed and subjected to immunoblot analysis for MITONEET and TOMM20.D,
MCF7 cells overexpressingHA-TOMM20were cultured and lysed and subjected to immunoblot analysis for TOMM20, TIGAR, and actin. E, ATP levelsmeasured
by quinacrine fluorescence intensity in TIGAR overexpressing and control MCF7 cells. Cell culture conditions as described above in B. F, ATP levels in TIGAR
overexpressing and control MCF7 cells with or without 10 M 3PO. n.s., not significant.
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coculture with T47D cells overexpressing TIGAR. Fibroblasts
exposed to carcinoma cells have reduced TIGAR expression,
but overexpression of TIGAR in fibroblasts led to 1.2-fold
reduced glucose uptake compared with control fibroblasts (Fig.
5E). In sum, TIGAR overexpression in carcinoma cells induced
a glycolytic phenotype in fibroblasts.
TIGAR Induced Tamoxifen Resistance but Higher Sensitivity
to Mitochondrial Modulators—T47D cells were cultured alone
or with fibroblasts and exposed to tamoxifen. TIGAR overex-
pression in carcinoma cells exposed to tamoxifen induced apo-
ptosis resistance with a 1.2-fold reduction in homotypic culture
and a 1.4-fold reduction in coculture with fibroblasts (p 0.05)
(Fig. 6A). In contrast, TIGAR-overexpressing carcinoma cells
weremore sensitive to apoptosis bymitochondrial modulators.
Metformin, which is an OXPHOS complex I inhibitor, doxycy-
cline, which inhibits mitochondrial translation, and ABT-199,
which inhibits BCL2 as a single agent or in combination
induced higher rates of apoptosis in TIGAR-overexpressing
T47D cells than controls (Fig. 6, B–E). Exposure to lactate in
MCF7 cells led to increased TIGAR and BCL2 expression with
reduced MCT4 expression (Fig. 6F). Exposure to tamoxifen in
MCF7 cells decreased expression of TIGAR, BCL-XL, BCL2,
MITONEET, and labile subunits of OXPHOS (Fig. 6, G–H).
Overexpression of MITONEET in MCF7 cells, which is a
marker of OXPHOS, reduced apoptosis rates in coculture with
tamoxifen 1.3-fold (p 0.05) (Fig. 6I).
TIGAR Overexpression Increased Xenograft Size—MDA-
MB-231, T47D, and MCF7 cells overexpressing TIGAR and
control cells were injected into the mammary gland of nude
female mice. MDA-MB-231 cells overexpressing TIGAR had
reduced Fru-2,6-P2 levels compared with controls (Fig. 7A).
MDA-MB-231 tumors with TIGAR-overexpressing carcinoma
cells had 2.5-fold greater volume (p  0.05) and 2.4 greater
weight (p 0.05) than control tumors (Fig. 7B).
TIGAR-overexpressing T47D tumors had higher TOMM20
expression than controls (Fig. 7C). TIGAR-overexpressing
T47D cells had reduced Fru-2,6-P2 levels compared with con-
trols (Fig. 7D). T47D tumors with TIGAR-overexpressing car-
cinoma cells had 3.5-fold greater volume (p 0.05) and 3.8-fold
greater weight (p 0.05) than control tumors (Fig. 7E). Mitotic
figures were increased 1.5-fold (p  0.05) in TIGAR overex-
pressing tumors compared with controls (Fig. 7F).
TIGAR-overexpressing MCF7 cells had reduced Fru-2,6-P2
levels compared with controls (Fig. 7G). MCF7 tumors with
TIGAR-overexpressing carcinoma cells had 7.8-fold greater
volume (p  0.05) and 5-fold greater weight (p  0.15) than
FIGURE 3. Effect of coculture with fibroblasts on proliferation and apoptosis of carcinoma cells. TIGAR and PFKFB3mRNA in T47D (A) and MCF7 (B) cells
in homotypic culture or coculture with fibroblasts. n.s., not significant. C, MCF7 cells were cultured with fibroblasts using an insert and lysed and subjected to
immunoblot analysis for TIGAR. D, DNA synthesis in carcinoma cells in homotypic culture or coculture with fibroblasts. T47D cells were cultured alone or in
coculture with fibroblasts for 4 days. DNA synthesis was measured with EdU incorporation and the cell cycle was assessed in carcinoma cells in homotypic
culture or coculture with fibroblasts. DNA synthesis was measured with EdU incorporation and ploidy assessment with propidium iodide. E, apoptosis in
carcinoma cells in homotypic culture or coculture with fibroblasts. T47D cells were cultured alone or in coculture with fibroblasts for 4 days. Apoptosis was
measuredwith annexin-V (AnnV) and propidium iodide (PI) staining. The percentage of apoptotic or dead T47D cells (annexin-V-positive and/or PI-positive) is
shown.
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control tumors (Fig. 7H). Mitotic figures were increased 5.6-
fold (p  0.05) in TIGAR-overexpressing tumors compared
with controls (Fig. 7I).
TIGAR-overexpressing T47D tumors had higher expression
of BCL2 than controls. Cells staining strongly positive for
BCL2 by digital pathology quantification (3 intensity) were
increased 3-fold in TIGAR-overexpressing tumors (p  0.05)
(Fig. 8A).
MDA-MB-231 cells overexpressingTIGARwith threemuta-
tions (H11A/E102A/H198A) that render it catalytically inactive
as a Fru-2,6-P2 bisphosphatase (TIGAR triple mutant) were
generated. The triple mutant TIGAR as expected did not
reduce Fru-2,6-P2 levels and did not increase tumor growth
compared with control carcinoma cells (Fig. 8B). Hence, a cat-
alytically active TIGAR is required to promote tumor growth.
Discussion
The current study delineates the role of TIGAR in OXPHOS
and glycolytic metabolic reprogramming in breast cancer.
This bisphosphatase enzyme, which reduces Fru-2,6-P2 levels,
inhibits glycolysis and increases pentose phosphate pathway
flux with increased NADP to NADPH production. We have
discovered that TIGAR promotes the growth of breast-invasive
ductal carcinoma in vivo and with utilization of lactate and glu-
tamine as substrates,mitochondrialOXPHOSmetabolism, and
ATP generation in cancer cells (Figs. 2 and 8C). Increased ATP
levels in TIGAR-overexpressing cells upon exposure to 3PO
suggests that TIGAR provides metabolic flexibility with
changes in Fru-2,6-P2 levels. We also demonstrate that TIGAR
expression in carcinoma cells induces reciprocal metabolic
changes in fibroblasts (Figs. 5 and 8D).
Our finding that TIGAR promotes growth of breast-invasive
ductal carcinoma is relevant to human disease because high
TIGAR expression is found in the majority of patients with
these tumors (8). A catalytically active TIGAR is required to
promote tumor growth. However, other activities of TIGAR
may also influence the biological properties of tumor cells.
Drugs targeting TIGAR’s bisphosphatase activity may be
beneficial in the management of breast-invasive ductal carci-
noma. Inhibitors of complex I of OXPHOS such as metformin,
of mitochondrial translation such as doxycycline, and BCL2
such as ABT-199 might have higher affinity in TIGAR-overex-
pressing tumors andwill need to be studied further. Conversely,
TIGAR overexpression induces resistance to the antiestrogen
drug tamoxifen in vitro, and future studies will need to deter-
mine whether TIGAR expression predicts responsiveness to
FIGURE 4. Effect of TIGAR on glycolysis andMCT1 in carcinoma cells. A, glucose uptake in TIGAR overexpressing carcinoma cells in coculture. RFP-tagged
fibroblasts were cocultured with T47D cells either overexpressing TIGAR or control T47D cells. NBDG uptake in T47D cells wasmeasured by flow cytometry. B,
lactate production in TIGAR overexpressing carcinoma cells. Lactate production in T47D cells was measured and normalized to cell number. C, lactate
production in HA-TOMM20-overexpressing carcinoma cells. Lactate production inMCF7 cells wasmeasured and normalized to cell number.D, MCF7-overex-
pressing TIGARand control T47Dcellswere cultured and lysed and subjected to immunoblot analysis forMCT1.MCF7with TIGARdown-regulation and control
cells using CRISPR-Cas9 were cultured and lysed and subjected to immunoblot for TIGAR (E) and MCT1 (F).
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tamoxifen in women with hormone receptor-positive breast
cancer. Resveratrol has been shown to reduce TIGAR expres-
sion, and research into drugs targeting TIGAR is being con-
ducted (29).
TIGAR is regulated by TP53, TP73, SP1, and AKT and indi-
rectly by MYC, c-Met, and miR-144 (7, 30–35). It is important
to note that although TP53 up-regulates TIGAR expression
experimentally, its expression in human breast cancer is
inversely correlated to the expression of TP53 (8). Future work
will need to determine themain drivers of TIGAR expression in
breast cancer.
TIGAR is an enzyme that reduces glycolysis (7). TIGARover-
expression in carcinoma cells reduced glycolysis, as expected
in the current study, and increased OXPHOS in these cells.
Aggressive cancer cells with low glycolysis and high pentose
phosphate activity have been described (36). High OXPHOS is
also associated with aggressive cancer (26, 37). The current
study demonstrates that TIGAR induces reciprocal metabolic
changes in adjacent fibroblasts with enhanced glycolysis
compared with the metabolic effects in carcinoma cells. The
increased fibroblast glycolysis in the current study occurred in
the context of increased PFKFB3 and LDH-A expression with
HIF1A activation. HIF1A is one of the main glycolytic tran-
scription factors, and it regulates the expression of PFKFB3 and
LDH-A. TIGAR in carcinoma cells also led to reduced LDH-B
and reduced TIGAR expression in fibroblasts which increase
glycolysis. It has been shown that glycolytic fibroblasts increase
breast cancer aggressiveness and tumor growth (38) (39). In
sum, the current study demonstrates that TIGAR induces
aggressive breast cancer with metabolic reprogramming of
the tumor microenvironment with low glycolysis in carci-
noma cells and opposite changes in stromal cells. Future
studies will need to determine the contribution of the meta-
bolic state of carcinoma cells and stromal cells to breast can-
cer tumor growth.
The current study demonstrates that TIGAR expression in
carcinoma cells reduces TIGAR expression in wild-type TP53
fibroblasts. TIGAR is regulated by TP53 (7). Additional factors
that regulate TIGAR expression in carcinoma cells are likely
to modulate TIGAR expression in fibroblasts. For example,
FIGURE 5. Effect of carcinomaTIGARexpressionon fibroblast glycolysis.A, glucose uptake in fibroblasts coculturedwith TIGAR-overexpressing carcinoma
cells. RFP-tagged fibroblastswere coculturedwithT47Dcells eitheroverexpressingTIGARor control T47Dcells. NBDGuptakewasmeasuredby flowcytometry.
B and C, fibroblasts with a GFP tag were cocultured with T47D cells either overexpressing TIGAR or control vectors. Fibroblasts were then lysed and subjected
to immunoblot analysis for PFKFB3 (B) and LDHA and LDHB (C). HIF1A luciferase reporter in fibroblasts in coculturewith carcinoma cells overexpressing TIGAR
or control vector. Coculture was performed in normoxia (21%O2) or hypoxia (0.5%O2) (D). E, glucose uptake in fibroblasts overexpressing TIGAR. Fluorescent
2-deoxyglucose uptake was measured by flow cytometry using 2-NBDG.
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TIGAR expression is also regulated by the transcription factors
MYC and SP1 (31, 33, 40, 41). TIGAR is also regulated byNFB
and PHD1 (42). Hence, MYC and SP1 may regulate TIGAR
expression in breast cancer-associated fibroblasts. Also, TP53
mutations in breast cancer-associated fibroblasts may alter
TIGAR expression as TP53 mutations and deletions alter
TIGAR expression in carcinoma cells (7, 22, 40). Carcinoma
cells favor the selection of fibroblasts lacking wild-type TP53
(43). TP53mutations have been demonstrated in breast cancer-
associated fibroblasts (44). In addition, fibroblasts from
patients with Li-Fraumeni syndrome have an abnormal TP53,
as the syndrome is due to germ line abnormalities in TP53. In
conclusion, high glycolysis in breast cancer-associated fibro-
blasts is induced by high TIGAR expression in carcinoma cells.
The role of additional modulators of glycolysis such as MYC,
SP1, and abnormal TP53 in breast cancer-associated fibroblasts
needs to be studied.
This study reveals that TIGAR can induce tumor metabolic
compartmentalization with highly glycolytic fibroblasts and
carcinoma cells with reduced glycolysis and high OXPHOS.
The effects of TIGAR on glycolysis, OXPHOS, and ATP are
similar to the changes in marker expression byWestern blot in
this study. HIF1A activation in fibroblasts was studied to deter-
mine the potential mechanisms by which TIGAR overexpres-
sion in carcinoma cells induces metabolic asymmetry with
increased fibroblast glycolysis. Glycolysis is induced upon
HIF1A activation (10) (45, 46). The current study demonstrates
that HIF1A is activated in fibroblasts when TIGAR is overex-
pressed in carcinoma cells. It has been previously shown that
HIF1A activation in breast cancer-associated fibroblasts pro-
motes tumor growth (47). The contribution of fibroblastHIF1A
activation to increased glycolysis, increased PFKFB3 expres-
sion, and tumor growth will need to be determined in future
studies.
FIGURE 6. Effect of TIGAR on chemotherapy-induced apoptosis. T47D cells overexpressing TIGAR or control T47D cells were cultured alone or in coculture
with fibroblasts for 2 days. Cells were incubated for 48 hwith andwithout 10M tamoxifen (A), 200Mmetformin (B), 15M doxycycline (C), 5M ABT-199 (D)
and with metformin, doxycycline, and ABT-199 (E). Apoptosis was measured with annexin-V and PI staining. The percentage of apoptotic or dead T47D cells
(annexin-V-positive and/or PI-positive) is shown. F, expression ofmetabolic andmitochondrial markers in carcinoma cells exposed to lactate. MCF7 cells were
culturedwithDMEMmediumwith 10%FBS overnight. Then cells were incubatedwith andwithout 10mM lactate for 48 h. Cells were then lysed and subjected
to immunoblot analysis for TIGAR, MCT4, and BCL2. Actin was used as loading control. G and H, expression of markers of mitochondrial function in carcinoma
cells exposed to tamoxifen. MCF7 cells were cultured with DMEM medium with 10% FBS overnight. Then cells were incubated with and without 10 M
tamoxifen for 48h. Cellswere then lysedand subjected to immunoblot analysis for TIGAR, BCL-XL, BCL2,MITONEET (G), andOXPHOS labile subunits (H). GAPDH
was used as loading control. I, MCF7 cells overexpressingMITONEET or control MCF7 cells were cultured alone or in coculture with GFP-tagged fibroblasts for
2 days. Then, cells were incubated with and without 10 M tamoxifen for 48 h. Apoptosis rate was measured as in A.
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In sum, the current study provides mechanistic information
on how TIGAR regulates fibroblast-carcinoma cell metabolic
interactions in breast cancer. It has long been recognized that
fibroblasts in proximity to cancer cells are pro-tumorigenic (4,
48). Most studies have focused on how fibroblast-secreted fac-
tors lead to a fibroblast-activated state that promotes tumor
growth (4, 49).We set out to determine how themetabolic state
of carcinoma cells modulates cancer aggressiveness and the
metabolic phenotype of fibroblasts. TIGAR expression in
breast carcinoma cells drives a mitochondrial OXPHOS phe-
notype in these carcinoma cells with a glycolytic phenotype in
fibroblasts with increased tumor growth in vivo. Further work
will need to determine the precise contribution of each of these
factors to cancer aggressiveness.
Experimental Procedures
Materials—Materials were obtained as follows: NADP/NA-
DPH quantification colorimetric kit (BioVision K347-100),
Click-iT EdU Flow Cytometry Assay kit (Life Technologies
C10418), lactate assay kit (EnzyChrom™ ECLC-100), quina-
crine dihydrochloride (Sigma, Q3251), 3PO (EMD 525330),
doxycycline (Sigma, D9891), metformin (Sigma D150959),
ABT-199 (Selleck Chemicals, S8048), TIGAR and PFKFB3
primers (Hs00608644 and Hs00190079, Applied Biosystems),
and MCT2 primers (forward sequence, GGTGATAGCAG-
GAGGCTTATT, and reverse sequence, GTTGCAGGTTGA-
AGGCTAAAC) (GeneCopoeia). Antibodies were obtained as
follows: GLS1 (ab60709, Abcam), MCT1 (SC-365501, Santa
Cruz Biotechnology), MCT2 (SC-50322, Santa Cruz Biotech-
nology),MCT4 (SC-50329, SantaCruz Biotechnology), LDH-A
(ab101562, Abcam), LDH-B (AV48210, Sigma), PGC1
(ab72230, Abcam), NRF1 (ab55744, Abcam), TIGAR (SC-
166291, Santa Cruz Biotechnology), TOMM20 (SC-17764,
Santa Cruz Biotechnology), MITONEET (16006–1-AP, Pro-
teintech), B-actin (A5441, Sigma), tubulin (T4026, Sigma),
GAPDH (CS 2118, Cell Signaling), OXPHOS labile subunit
FIGURE 7. Effect of TIGAR in carcinoma cells on orthotopic tumor growth and proliferation. A, Fru-2,6-P2 levels. MDA-MB-231 cells overexpressing TIGAR
or empty vector control were cultured, and Fru-2,6-P2 levels weremeasured. B, tumor growth. MDA-MB-231 cells overexpressing TIGAR (MDA-MB-231-TIGAR)
or empty vector control were injected into the mammary fat pad of nude mice. Tumor volume and weight were measured after resection at 4 weeks
post-injection.C, TOMM20 expression. T47D tumors overexpressing TIGARor empty vector control tumor sectionswere stained by immunohistochemistry for
TOMM20. Originalmagnification is 40.D, Fru-2,6-P2 levels in T47D-TIGAR or control cells. E, tumor growth. T47D-TIGAR or control cells were injected into the
mammary fat pad of nude mice. Tumor volume and weight were measured after resection at 4 weeks post-injection. F, proliferation rates. Mitotic figures in
T47D tumorswere quantified per high power field.G, Fru-2,6-P2 levels. MCF7 cells overexpressing TIGAR or empty vector control were cultured, and Fru-2,6-P2
levels were measured. H, tumor growth. MCF7-TIGAR or control cells were injected into the mammary fat pad of nude mice. Tumor volume and weight were
measured after resection at 4 weeks post-injection. I, proliferation rates. Mitotic figures in MCF7 tumors were quantified per high power field.
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mixture (MS601, Abcam), BCL2 (ab7973 and ab182858,
Abcam for immune blot and immunohistochemistry, respec-
tively), and BCL-XL (CS 2764, Cell Signaling).
Cell Culture—The human breast carcinoma cell lines (T47D,
MCF7, and MDA-MB-231) were purchased from ATCC.
Human skin fibroblasts immortalized with human telomerase
reverse transcriptase catalytic domain (hTERT-BJ1) were pur-
chased from Clontech, and clones were generated with green
fluorescent protein (GFP) or red fluorescent protein (RFP)
overexpression. Cells were passaged for fewer than 6 months
after resuscitation. Cells were cultured in media containing 5
mM glucose and 1 mM pyruvate, 10% fetal bovine serum, 100
units/ml penicillin, and 100 units/ml streptomycin in a 37 ºC,
5% CO2 incubator. RPMI 1640 was the base medium for T47D
cells and DMEM for MCF7 and MDA-MB-231 as recom-
mended by ATCC. To study the effect of lactate and glutamine,
control conditions were compared with those with 2 mM gluta-
mine or 10 mM lactate or 2 mM glutamine plus 10 mM lactate.
Co-culture System—Fibroblasts and carcinoma cells were
cocultured as previously described (50). Briefly, cells were
seeded at a 3:1 fibroblast to carcinoma cell ratio, and the total
number of cells per well was 1  105. As controls, cultures of
fibroblasts and carcinoma cells alone were plated in parallel
with the same number of cells of a given type as in coculture
(7.5 104 fibroblasts and 2.5 104 carcinoma cells).
Messenger RNA Quantification—Total RNA was extracted
using the RNeasy Mini Kit(Qiagen). Complementary DNA
(cDNA)was randomly primed from2.0g of total RNAusing the
SuperScript III First-Strand Synthesis System for RT-PCR (Invit-
rogen). Real-time PCRwas performed in triplicate with a 1:3 dilu-
tion of cDNA using the Power SYBRGreen PCR system. Relative
expression levels were determined using the comparative Ct
method.AllmRNAquantification datawere normalized to-actin.
TIGAR, TOMM20, and MITONEET Overexpression and
TIGAR Down-regulation—TIGAR (EX-W1314-Lv105), TIGAR
triple mutant (H11A/E102A/H198A, CS-W1314-Lv105),
FIGURE 8. TIGAR and BCL2, tumor growth with catalytically inactive TIGAR, and models of TIGAR effects on carcinoma and fibroblast cells. A, BCL2
expression. Tumor sections were stained by immunohistochemistry for BCL2. Original magnification is 40. The percentage of cells with the strongest BCL2
protein expression was quantified by Aperio digital pathology (3 intensity percentage). B, Fru-2,6-P2 levels and tumor growth. MDA-MB-231 cells overex-
pressing triplemutant TIGARwith H11A/E102A/H198Amutations (MDA-MB-231-TIGAR-3M) or empty vector control were cultured, and Fru-2,6-P2 levels were
measured. MDA-MB-231 cells overexpressing triplemutant TIGAR (MDA-MB-231-TIGAR-3M) or empty vector control were injected into themammary fat pad
of nudemice. Tumor volume andweight weremeasured after resection at 4 weeks post-injection. No statistically significant change in volume or weight was
notedbetween triplemutant TIGAR and control cells.C, amodel is shownof howTIGAR expression in carcinoma cells reduces glycolysis, increases the pentose
phosphate pathway activity, and increases mitochondrial oxidative phosphorylation. D, high TIGAR expression in carcinoma cells alters their metabolic state
and induces cancer aggressiveness. Conversely, fibroblasts in proximity to carcinoma cells have reciprocal metabolic changes.
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MITONEET (EX-V0831-Lv105), empty vector control (EX-
NEG-Lv105), HA-TOMM20 (EX-G0283-Lv120), HA control
(EX-NEG-LV120) vectors and Cas9 nuclease lentiviral expres-
sion clone (CP-LvC9NU-01), Sg RNA lentiviral expression
targeting C12orf5 (HCP215394-LvSG03-3-10), and Sg RNA
lentiviral control (CCPCTR01-LvSG03) were purchased from
GeneCopoeia, and lentiviruses were prepared according to the
manufacturer’s protocol. Virus-containing media were centri-
fuged, filtered (0.45 M polyethersulfone (PES) low protein fil-
ter), and stored in 1-ml aliquots at 80 °C. Carcinoma cells
(120,000 cells/well) were plated in 12-well dishes in growth
media. After 24 h themediawas removed and replacedwith 250
l of media with 5% FBS, 150l of virus-containingmedia, and
5 g/ml Polybrene. 24 h post-infection the media-containing
virus was removed and replaced with growth media. The cells
were selected with puromycin (2 g/ml) for 3 days after
infection.
Measurement of NADP/NADPH Ratio—Plated cells were
washed and centrifuged at 2000 rpm for 5 min. Extraction
buffer was admixed with two freeze and thaw cycles. NADP
cycling enzyme was added as well as the NADPH developer,
and measurement was at A450 nm.
OCR Assessment—A Seahorse Bioscience XF96 Extracellular
Flux Analyzer in a 24-well format was used. T47D cells were
preseeded in the XF24 24-well plate with 100 l of RPMI 1640
media with 10% fetal bovine serum, 100 units/ml penicillin, 100
units/ml streptomycin, 1 mM pyruvate and additional 2 mM
glutamine and/or 10 mM lactate in a 37 ºC, 5% CO2 incubator
for 2 h. After 2 h, an additional 200 l of growth medium was
added for a total volume of 300 l per well. On the second day,
cells were incubated in non-buffered RPMI 1640 media for 2 h.
Measurementswere obtained under basal conditions.OCRwas
normalized to total protein content. Statistical significance was
examined using Student’s t test. Values of p  0.05 were con-
sidered significant.
ATP Assay—Intracellular ATP levels were measured using
the ATP-sensitive fluorochrome quinacrine. Briefly, cells were
incubated with 20 M quinacrine dihydrochloride at 37 ºC for
1 h, and green fluorescence intensity was measured by flow
cytometry as previously described (51).
Apoptosis Assessment—Apoptosis in culture was quantified
by flow cytometry using PI and annexin-V-APC as previously
described (50).
Measurement of Glucose Uptake—2-NBDG, which is green flu-
orescent 2-deoxyglucose,wasutilized aspreviously described (47).
Proliferation Assessment—For DNA content and prolifera-
tion analyses, cells were incubated with EdU (Click-iT EdU
FlowCytometryAssay kits) for 1 h. Then cells were stainedwith
propidium iodide and anti-EdU-APC antibody. Cells were then
analyzed by flow cytometry for nascent DNA synthesis (EdU
incorporation) and ploidy assessment (PI). Proliferating cells in
the xenograft tumors were identified on the basis of mitotic
figures. Cells were counted in all fields within the central area of
each tumor excluding regions with stromal elements using a
20 objective lens and an ocular grid (0.25 mm2 per field). The
total numbers of mitotic figures per unit area was calculated,
and the data were represented graphically.
Two Cell Populations Sorting by Flow Cytometry—Fibro-
blasts with an RFP tag were cultured alone or in coculture with
carcinoma cells for 4 days. Two cell populations were separated
by flow cytometry through sorting with RFP-positive and RFP-
negative cells. The presence of RFP in fibroblasts and lack of
color in carcinoma cells allows us to separate these two cell
populations in the flow cytometry cell sorter. After cell sorting,
cells were then lysed and subjected to immunoblot analysis.
Measurement of Lactate Production—10  104 of cells were
plated in each well of a 12-well plate with cell culture medium,
and on the 2nd day the medium was changed to RPMI 1640
with 2% FBS. After 24 h, cell media were collected and lactate
production was analyzed as described (47).
Luciferase Activity—NIH3T3 fibroblasts stably transfected
with a HIF1A luciferase reporter (RC0017, Panomics) were
seeded in co-culture with carcinoma control or carcinoma
TIGAR carcinoma cells. As controls, fibroblasts were plated in
mono-culture using the same cell numbers as in the corre-
sponding co-cultures. Luciferase activity was measured as pre-
viously described (52).
Fru-2,6-P2 Determination—Fru-2,6-P2 was determined as
previously described (53), and protein concentrationwas deter-
mined by the Bradford assay (Bio-Rad).
Immunohistochemistry—Sections were deparaffinized, rehy-
drated through graded ethanol, and washed in PBS. Antigen
retrieval was performed in 0.01 M citrate buffer, pH 6.0, for 10
min using a pressure cooker followed by blocking for endoge-
nous peroxidase in 3% H2O2 for 15 min. An avidin-biotin kit
(Biocare Medical) was used to block endogenous biotin. For
BCL2 rabbit antibody (ab 182858, Abcam), sections were
blocked with 10% goat serum and incubated with antibody for
1 h at room temperature. After washing in PBS, the sections
were incubated with biotinylated goat anti-rabbit IgG (Vector
Laboratories) for 30 min and then avidin-horseradish peroxi-
dase complex (Vectastain Elite ABC kit, Vector) for 30 min.
Antibody reactivity was detected using liquid DAB substrate
chromagen (Dako). For TOMM20 the VectorM.O.M. Basic kit
was used followed by ABC and DAB detection. Quantitative
analysis of immunohistochemistry was performed employing
Aperio software as previously described (54). Increasing inten-
sity using Aperio was quantified as 0, 1, 2 and 3.
Animal Studies—To evaluate the in vivo tumor-promoting
effects of TIGAR, mammary gland injections were performed
on female athymicNCr nudemice (NCRNU; Taconic Farms; at
6 weeks of age). All animals weremaintained in a pathogen-free
environment/barrier facility at the Kimmel Cancer Center at
Thomas Jefferson University. Experiments were performed
according toNational Institutes ofHealth guidelines. The Insti-
tutional Animal Care and Use Committee (IACUC) approved
all animal protocols. MDA-MB-231, MCF7, and T47D cells
were injected into the mammary fat pads of nude mice. Cancer
cells (1 million cells) and (0.3 million) hTERT-BJ1 fibroblasts
were resuspended in 100 l of sterile PBS just before injection
into the mammary fat pad. Oophorectomy and estrogen
supplementation with 17-estradiol pellet placement (0.72
mg/pellet) were performed before injection of the estrogen
receptor-positive cell lines MCF7 and T47D as previously
described (23). After 4 weeks post-injection, tumors were
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excised to determine their weight and size. Volumes were cal-
culated using the formula V  (X2Y)/2, where V is the tumor
volume, x is the length of the short axis, and y is the length of the
long axis using electronic calipers. Statistical significance was
examined using the Mann-Whitney U test. Values of p  0.05
were considered significant.
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